333 completed. 333 Phase 1, 87 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 333 | Completed 333 |
| Phase 2 | 87 | Completed 87 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Fludarabine, Cyclophosphamide, PRGN-3007 - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2023-01-25 | 2026-02-06 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma Glofitamab, Obinutuzumab, Tocilizumab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Hoffmann-La Roche | 43 | 2022-11-04 | 2025-12-01 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL KT-413 - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Kymera Therapeutics, Inc. | 7 | 2022-06-13 | 2024-12-10 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies AB308, Zimberelimab - Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | Arcus Biosciences, Inc. | 94 | 2021-03-19 | 2025-08-28 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL FT596, Rituximab - NHL, Non Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 7 | 2020-09-22 | 2024-07-09 |
| Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Zanubrutinib, Lenalidomide - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | BeiGene | 66 | 2020-09-11 | 2025-05-23 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
| CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) - Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2020-07-10 | 2023-11-22 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies YY-20394 - Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma | Phase 1 | Completed | Shanghai YingLi Pharmaceutical Co. Ltd. | 43 | 2020-06-15 | 2024-06-13 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab BGB-10188, Zanubrutinib, Tislelizumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 97 | 2020-04-29 | 2026-02-20 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels Tazemetostat, Itraconazole, Rifampin - All Malignancies, Advanced Malignancies | Phase 1 | Completed | Epizyme, Inc. | 42 | 2020-04-23 | 2025-02-19 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) BR101801 (Phase Ia), BR101801 (Phase Ib) - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 26 | 2020-04-21 | 2025-09-10 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia TC-110 T Cells, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | TCR2 Therapeutics | 6 | 2020-03-27 | 2023-03-16 |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Tafasitamab, Tafasitamab plus lenalidomide - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | MorphoSys AG | 66 | 2019-12-11 | 2024-10-16 |
| A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL OPB-111077 - Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Otsuka Pharmaceutical Co., Ltd. | 36 | 2019-11-22 | 2026-04-08 |
Showing 20 of 333. Sign in to see all of them.
Lymphoma, Follicular (221) · Lymphoma, Mantle-Cell (215) · Lymphoma, Non-Hodgkin (193) · Leukemia, Lymphocytic, Chronic, B-Cell (179) · Burkitt Lymphoma (173) · Lymphoma, B-Cell, Marginal Zone (173) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (162) · Lymphoma (153) · Lymphoma, Large-Cell, Immunoblastic (148) · Hodgkin Disease (137) · Lymphoma, Large-Cell, Anaplastic (92) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (92) · Lymphoma, T-Cell, Cutaneous (91) · Mycosis Fungoides (84)
Hemic and Lymphatic Diseases (333) · Neoplasms by Histologic Type (332) · Immune System Diseases (330) · Lymphatic Diseases (330) · Immunoproliferative Disorders (329) · Lymphoproliferative Disorders (326) · Lymphoma, B-Cell (316) · Neoplasms (311) · Hematologic Diseases (219) · Leukemia, Lymphoid (199) · Pathologic Processes (198) · Pathological Conditions, Signs and Symptoms (198) · Disease Attributes (197) · Chronic Disease (183) · Lymphoma (180)
Rituximab (55) · Cyclophosphamide (41) · Etoposide (24) · Vincristine (20) · Peripheral Blood Stem Cell Transplantation (19) · Prednisone (19) · Filgrastim (18) · Lenalidomide (18) · fludarabine phosphate (18) · Doxorubicin (17) · Bortezomib (14) · Carboplatin (13) · ibrutinib (13) · Vorinostat (12) · Bendamustine Hydrochloride (11)
National Cancer Institute (NCI) (53) · Fred Hutchinson Cancer Center (12) · Memorial Sloan Kettering Cancer Center (12) · Mayo Clinic (10) · National Institutes of Health Clinical Center (CC) (10) · Celgene (7) · Northwestern University (7) · Case Comprehensive Cancer Center (6) · City of Hope Medical Center (6) · Hoffmann-La Roche (6) · M.D. Anderson Cancer Center (6) · Masonic Cancer Center, University of Minnesota (5) · Regeneron Pharmaceuticals (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Amgen (4)
United States (288) · United Kingdom (23) · France (22) · Canada (17) · Italy (17) · Spain (17) · Germany (16) · China (10) · South Korea (10) · Australia (9) · Netherlands (7) · Japan (6) · Belgium (5) · Poland (4) · Switzerland (4)
Shivaani Kummar, MD (4) · Edward A. Sausville, MD, PhD (3) · Peter Martin, MD (3) · Ajay Gopal (2) · Alex A. Adjei, MD, PhD (2) · Brenda Sandmaier (2) · Claudio G. Brunstein, MD, PhD (2) · David Bond, MD (2) · David R. Spriggs, MD (2) · Ephraim J. Fuchs, MD (2) · Franco M. Muggia, MD (2)
PMID 34515338, PMID 19949018, PMID 20028764, PMID 22002018, PMID 32499241, PMID 34310745, PMID 34493319, PMID 40802906, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11756154, PMID 12171484, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15570084, PMID 16135477, PMID 16731764, PMID 17119113, PMID 17312328, PMID 17515574, PMID 17947483, PMID 18327587, PMID 18463792, PMID 18470481, PMID 18974373, PMID 19179301, PMID 19238148, PMID 19451403, PMID 19451441, PMID 19652067, PMID 19789320, PMID 20952687, PMID 21247755, PMID 21403127, PMID 21498721, PMID 22259028, PMID 22430088, PMID 22775314, PMID 22965964, PMID 23592273, PMID 24057042, PMID 24072436, PMID 24352795, PMID 24474568, PMID 24530971, PMID 24530972, PMID 25042202, PMID 25135992
2015 (6), P30CA015704 (6), P30CA015083 (5), P30CA033572 (5), U01CA099168 (5), 2016 (4), 2017 (4), P30CA006973 (4), P30CA016672 (4), U01CA062487 (4), U01CA062491 (4), U01CA062502 (4), U01CA069912 (4), U01CA097452 (4), P30CA008748 (3)